Cargando…
NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy
BACKGROUND: NKTR-255 is a novel polyethylene glycol-conjugate of recombinant human interleukin-15 (rhIL-15), which was designed to retain all known receptor binding interactions of the IL-15 molecule. We explored the biologic and pharmacologic differences between endogenous IL-15 receptor α (IL-15Rα...
Autores principales: | Miyazaki, Takahiro, Maiti, Mekhala, Hennessy, Marlene, Chang, Thomas, Kuo, Peiwen, Addepalli, Murali, Obalapur, Palakshi, Sheibani, Sara, Wilczek, Joanna, Pena, Rhoneil, Quach, Phi, Cetz, Janet, Moffett, Andrew, Tang, Yinyan, Kirk, Peter, Huang, Jicai, Sheng, Dawei, Zhang, Ping, Rubas, Werner, Madakamutil, Loui, Kivimäe, Saul, Zalevsky, Jonathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130760/ https://www.ncbi.nlm.nih.gov/pubmed/34001523 http://dx.doi.org/10.1136/jitc-2020-002024 |
Ejemplares similares
-
Bempegaldesleukin (BEMPEG; NKTR‐214) efficacy as a single agent and in combination with checkpoint‐inhibitor therapy in mouse models of osteosarcoma
por: Hennessy, Marlene, et al.
Publicado: (2020) -
NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases
por: Dixit, Neha, et al.
Publicado: (2021) -
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8(+) T cell cytotoxicity over BEMPEG+RT
por: Rolig, Annah S, et al.
Publicado: (2022) -
Synergistic antitumor activity of the CD122-biased immunostimulatory cytokine NKTR-214 when combined with anti-PD-1 in murine tumor models
por: Murali, Addepalli, et al.
Publicado: (2015) -
Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15
por: Fernandez, Rafael Alonso, et al.
Publicado: (2022)